Subcutaneous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy

Area of Science:

• Neurology
• Immunology
• Clinical Trials

Background:

• Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune-mediated neuropathy causing progressive weakness and sensory loss.
• Intravenous immunoglobulin (IVIg) is a standard first-line treatment for CIDP.
• Subcutaneous immunoglobulin (SCIg) offers potential advantages in administration and patient quality of life.

Purpose of the Study:

• To evaluate the efficacy and safety of subcutaneous immunoglobulin (SCIg) for induction and maintenance treatment in CIDP.
• To compare SCIg against placebo or other interventions in randomized controlled trials (RCTs).

Main Methods:

• Systematic review and meta-analysis of RCTs comparing SCIg with placebo or other treatments in probable or definite CIDP.
• Primary outcomes: improvement in disability (induction) and clinically significant deterioration in disability (maintenance).
• Secondary outcomes: grip strength, disability scores, and adverse effects; assessed using Cochrane risk of bias and GRADE criteria.

Main Results:

• SCIg maintenance therapy likely reduces disability deterioration versus placebo (RR 0.40, moderate certainty).
• SCIg likely improves grip strength and disability scores compared to placebo (moderate certainty).
• SCIg is associated with a probable increase in local adverse effects but no difference in systemic effects (moderate certainty).

Conclusions:

• Evidence for SCIg as induction therapy is lacking; its efficacy versus IVIg remains unclear.
• SCIg maintenance therapy appears effective in reducing disability worsening and improving function, with manageable local side effects.
• Further RCTs are needed to compare SCIg with placebo/other induction treatments and to assess its long-term benefits against other maintenance therapies.